Glow Blend
BPC-157 + Tb-500 + GHK-Cu
In short
- BPC-157 plus TB-500 plus GHK-Cu — the Wolverine repair pairing with a copper peptide added for skin.
- GHK-Cu's evidence is TOPICAL, in cosmetic dermatology. Putting it in an injectable blend moves it away from the route its evidence supports.
- The copper content is the specific consideration: copper has a narrow safe range, and injecting a copper complex repeatedly is uncharacterised.
- At 15 mg per vial, GHK-Cu is the largest component by mass in this blend.
- Prohibited in sport, because TB-500 is explicitly prohibited at all times.
Structure
A blend of three peptides. See the BPC-157, TB-500 and GHK-Cu entries for their individual structures.
How it works
BPC-157 and TB-500 supply the repair rationale described in the Wolverine entry — angiogenesis and cell migration respectively.
GHK-Cu is a copper-binding tripeptide that stimulates collagen and glycosaminoglycan synthesis in fibroblasts. Copper is a required cofactor for lysyl oxidase, which cross-links collagen and elastin, giving a plausible route to dermal effects.
The blend rationale is that repair plus skin support addresses recovery and appearance together. No study has tested the three-component combination.
What the research shows
No study has tested this specific combination in humans. Whatever evidence exists belongs to the individual components, tested individually.
GHK-Cu has genuine controlled human evidence — for topical application, with cosmetic-scale endpoints over roughly 12 weeks. That evidence does not transfer to injection.
BPC-157 and TB-500 have the limited evidence described in their own entries.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Human — GHK-Cu topical cosmetic studies (not injected) | 1–3 mg/mL topical, twice daily for 12 weeks | topical | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported combined daily dosing | Drawn to deliver roughly 250 µg BPC-157, 400 µg TB-500, 1–2 mg GHK-Cu | subcutaneous |
No study has tested this specific combination in humans. Whatever evidence exists belongs to the individual components, tested individually. A pre-mixed vial fixes the ratio between components at whatever the vendor chose. You can change the total volume you draw, but you cannot change the proportions — so if one component suits you at a different relative amount, a blend cannot express that. Buying components separately costs more vials and buys back that control. The specific issue with this blend is copper: GHK-Cu is the dominant component by mass, and repeated injection of a copper complex has never been characterised for its effect on copper status. Topical application does not raise systemic copper meaningfully; injection is a different exposure.
Handling and storage
Supplied as a lyophilised powder requiring reconstitution with bacteriostatic water. The powder is comparatively stable; once reconstituted it is refrigerated and used within weeks. Track the date you reconstitute each vial — the Inventory section does this, and it is the difference between knowing a vial is three weeks old and guessing.
The reconstituted solution is a distinctive blue from the copper complex — that colour is expected, not contamination.
GHK-Cu is commonly reported to sting more on subcutaneous injection than other peptides, consistent with its copper content.
Side effects
Injection-site irritation is more commonly reported for this blend than for Wolverine, attributable to the copper peptide.
The systemic consideration is copper accumulation. Copper is essential but has a narrow therapeutic window, and chronic excess causes hepatic and neurological toxicity. Wilson disease or any disorder of copper handling is a clear reason to avoid systemic use.
The angiogenesis-related theoretical concern applies to all three components — GHK-Cu is also described as promoting angiogenesis, so this blend stacks that consideration three ways.
Combinations
Running components together makes attribution impossible in both directions. If something improves you cannot tell which component did it, and if something goes wrong you cannot tell which one to stop. Blends are convenient and they are also the format that teaches you least about your own response.
Research status
GHK-Cu has the best evidence of the three components, and it is topical and cosmetic. BPC-157 and TB-500 are covered in their own entries.
The three-way combination has no research.
Legal status
None of the components is approved as an injectable drug anywhere. GHK-Cu is permitted and widely used as a cosmetic ingredient. Sold for research use only.
WADA status
PROHIBITED. TB-500 is explicitly prohibited at all times under WADA class S2, which makes the blend prohibited regardless of the other components.
Conclusion
Glow takes the compound in this library with the best human evidence — GHK-Cu topically — and puts it in a syringe, where that evidence no longer applies.
If skin is the goal, the topical route is the one with controlled trials behind it, and it avoids the copper-load question entirely.
Sources
Track your own Glow Blend protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.